Category Archives: U.S. Policy and Funding

Gilead hepatitis C drug price deal leaves global treatment access advocates underwhelmed

By on .

When the U.S. Food and Drug Administration approved sofosbuvir for the treatment of chronic hepatitis C in early December, it was a step that was “expected to dramatically improve outcomes for many patients,” as one report put it. But how many was a big question, as we noted here. While the drug shortens treatment for […]